Literature DB >> 17031846

A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses.

Deliang Zhou1, David J W Grant, Geoff G Z Zhang, Devalina Law, Eric A Schmitt.   

Abstract

The purpose of this work was to investigate the contribution of thermodynamics and mobility to the physical stability of two pharmaceutical glasses with similar glass transition temperatures (Tg), by comparing configurational thermodynamic quantities and molecular relaxation time constants (tau) at temperatures below Tg. Ritonavir and nifedipine were chosen as model glasses because they show excellent and poor physical stability, respectively. Although ritonavir and nifedipine have similar Tg values (50 and 46 degrees C, respectively), amorphous ritonavir is quite stable while nifedipine has been reported to crystallize at temperatures as low as 40 degrees C below Tg. Modulated temperature differential scanning calorimetry (MTDSC) was used to characterize both crystalline phases and freshly prepared glasses. The glasses were then annealed at Tg-Ta = 25 degrees C while monitoring the extent of relaxation and heat capacity change as a function of time via MTDSC. Configurational thermodynamic quantities (Gc, Hc, and Sc) and molecular relaxation time constants, tau, were calculated from the calorimetric data. Interestingly, the Gibbs free energy driving force for crystallization was nearly identical for the two compounds. The largest differences were found in the configurational entropy (Sc) values for the fresh glasses and in the Sc values over time. Configurational entropy values were approximately 50% higher for ritonavir. The tau values of freshly prepared glasses indicated that both materials had similar initial mobility at the annealing temperatures and the temperature dependence of tau was approximately Arrhenius, regardless of age. Although initial tau values were similar, the tau values after 3 days annealing were approximately sixfold greater for ritonavir. The relatively poor physical stability of nifedipine compared to ritonavir is attributed to both the lower entropic barrier to crystallization for fresh and annealed glass, and higher molecular mobility in aged glasses of nifedipine. These observations below Tg are consistent with the previous work on physical stability of amorphous pharmaceuticals performed above Tg. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17031846     DOI: 10.1002/jps.20633

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Role of viscosity in influencing the glass-forming ability of organic molecules from the undercooled melt state.

Authors:  Jared A Baird; Darlene Santiago-Quinonez; Carlos Rinaldi; Lynne S Taylor
Journal:  Pharm Res       Date:  2011-07-22       Impact factor: 4.200

2.  Dissolution improvement of electrospun nanofiber-based solid dispersions for acetaminophen.

Authors:  Deng-Guang Yu; Christopher Branford-White; Kenneth White; Xue-Lian Li; Li-Min Zhu
Journal:  AAPS PharmSciTech       Date:  2010-05-06       Impact factor: 3.246

Review 3.  Second-order nonlinear optical imaging of chiral crystals.

Authors:  David J Kissick; Debbie Wanapun; Garth J Simpson
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2011       Impact factor: 10.745

4.  Optimizing the Formulation for Ginkgolide B Solid Dispersion.

Authors:  Xiao Wu; Qing Huo; Qizhe Quan; Xiaofang Yang; Na Yu; Yue Wang
Journal:  Open Life Sci       Date:  2018-08-21       Impact factor: 0.938

5.  Potential of solid dispersions to enhance solubility, bioavailability, and therapeutic efficacy of poorly water-soluble drugs: newer formulation techniques, current marketed scenario and patents.

Authors:  Sultan Alshehri; Syed Sarim Imam; Afzal Hussain; Mohammad A Altamimi; Nabil K Alruwaili; Fahad Alotaibi; Abdullah Alanazi; Faiyaz Shakeel
Journal:  Drug Deliv       Date:  2020-11-09       Impact factor: 6.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.